Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-81795 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-81795, RRID:AB_11012511
- Product name
- Rabbit Polyclonal Trim22 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Specificity of human Trim22 antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis.
TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment.
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction.
Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection.
The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase.
Zhang L, Zhang B, Wei M, Xu Z, Kong W, Deng K, Xu X, Zhang L, Ζhao X, Yan L
International journal of oncology 2020 May;56(5):1225-1239
International journal of oncology 2020 May;56(5):1225-1239
TRIM5α and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment.
Singh R, Patel V, Mureithi MW, Naranbhai V, Ramsuran D, Tulsi S, Hiramen K, Werner L, Mlisana K, Altfeld M, Luban J, Kasprowicz V, Dheda K, Abdool Karim SS, Ndung'u T
Journal of virology 2014 Apr;88(8):4291-303
Journal of virology 2014 Apr;88(8):4291-303
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction.
Carotenuto M, Pedone E, Diana D, de Antonellis P, Džeroski S, Marino N, Navas L, Di Dato V, Scoppettuolo MN, Cimmino F, Correale S, Pirone L, Monti SM, Bruder E, Zenko B, Slavkov I, Pastorino F, Ponzoni M, Schulte JH, Schramm A, Eggert A, Westermann F, Arrigoni G, Accordi B, Basso G, Saviano M, Fattorusso R, Zollo M
Scientific reports 2013;3:1351
Scientific reports 2013;3:1351
Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection.
Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, Walker BD, Karim SS, Brass AL, Ndung'u T, CAPRISA Acute Infection Study Team.
Journal of virology 2011 Jan;85(1):208-16
Journal of virology 2011 Jan;85(1):208-16
The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase.
Petersson J, Lönnbro P, Herr AM, Mörgelin M, Gullberg U, Drott K
Experimental cell research 2010 Feb 15;316(4):568-79
Experimental cell research 2010 Feb 15;316(4):568-79
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Trim22 Antibody [NBP1-81795] - Lane 1: Marker [kDa] 220, 112, 84, 47, 32, 26, 17. Lane 2: Human cell line RT-4
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Trim22 Antibody [NBP1-81795] - Analysis in U-87MG ATCC cells transfected with control siRNA, target specific siRNA probe #1 and #2, using anti-TRIM22 antibody. Remaining relative intensity is presented. Loading control: anti-PPIB.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: Trim22 Antibody [NBP1-81795] - Staining of human bone marrow shows strong nuclear positivity in hematopoietic cells.
